Entrada Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Entrada Therapeutics Depreciation & Amortization Growth & History (TRDA)
Entrada Therapeutics's depreciation and amortization was $4.1M for fiscal 2025.
View full Entrada Therapeutics company overviewEntrada Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.1M | $323,000 | +8.56% |
| 2024 | 2024-12-31 | $3.8M | $932,000 | +32.81% |
| 2023 | 2023-12-31 | $2.8M | $946,000 | +49.92% |
| 2022 | 2022-12-31 | $1.9M | $778,000 | +69.65% |
| 2021 | 2021-12-31 | $1.1M | $791,000 | +242.64% |
| 2020 | 2020-12-31 | $326,000 | — | — |
Entrada Therapeutics quarterly depreciation and amortization
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $800,000 | −$300,000 | −27.27% |
| Q1 2026 | 2026-03-31 | $805,000 | −$141,000 | −14.90% |
| Q4 2025 | 2025-12-31 | $886,000 | — | — |
| Q3 2025 | 2025-09-30 | $1.2M | $300,000 | +33.33% |
| Q2 2025 | 2025-06-30 | $1.1M | $200,000 | +22.22% |
| Q1 2025 | 2025-03-31 | $946,000 | $12,000 | +1.28% |
| Q3 2024 | 2024-09-30 | $900,000 | $100,000 | +12.50% |
| Q2 2024 | 2024-06-30 | $900,000 | $200,000 | +28.57% |
| Q1 2024 | 2024-03-31 | $934,000 | $393,000 | +72.64% |
| Q3 2023 | 2023-09-30 | $800,000 | $300,000 | +60.00% |
| Q2 2023 | 2023-06-30 | $700,000 | $200,000 | +40.00% |
| Q1 2023 | 2023-03-31 | $541,000 | $151,000 | +38.72% |
| Q3 2022 | 2022-09-30 | $500,000 | $200,000 | +66.67% |
| Q2 2022 | 2022-06-30 | $500,000 | $200,000 | +66.67% |
| Q1 2022 | 2022-03-31 | $390,000 | $191,000 | +95.98% |
| Q3 2021 | 2021-09-30 | $300,000 | $200,000 | +200.00% |
| Q2 2021 | 2021-06-30 | $300,000 | — | — |
| Q1 2021 | 2021-03-31 | $199,000 | — | — |
| Q3 2020 | 2020-09-30 | $100,000 | — | — |
Entrada Therapeutics depreciation and amortization trends
Over the last five fiscal years, Entrada Therapeutics's depreciation and amortization increased from $326,000 to $4.1M, a change of $3.8M. The latest reported quarter, Q2 2026, shows $800,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Entrada Therapeutics source filings ↗